VBLT - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the VBL Therapeutics Fourth Quarter and Full-Year 2020 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. conference the the team. turn now over VBL to I’ll

You may begin.

Lee Roth

and Good Shemali. today’s once quarter call results this morning Dror Leading again be conference you, corporate VBL XXXX update and thank fourth morning for and the us everyone Thank call. financial joining you Therapeutics Professor will full-year Harats, for available full-year press on vblrx.com. morning company's financial the Executive and Ron, Amos with page this Relations Officer Investor earlier Chief for the release XXXX the of Chief and at issued is Financial Officer. A website was results our

Private call of to fall Litigation that to made XXXX XXXX of the Act turn I XXE Reform remind forward-looking management to by I’d within everyone the Before the Act this statements Securities call, Securities Section over Exchange the and as management, safe intended like of harbor are amended. during of provisions

events as the circumstances XX not this As website. and our in made are set our uncertainties Exchange press on affect available and call the update Securities or after or things, any date, the to include may the XXXX. Commission, intend XX-F. These forward-looking Form statements today's Any statements reflect including speak Report that forward-looking forward-looking SEC risks involve via And to on and the which does only of March prospects, among release, statements forth on filings with in other company these company's Annual those business that filings our today. discussed of occur

prepared With Professor call turn There session rebroadcast pleasure my being for will that on website. said, recorded company's Harats, the reminder, and remarks. is it's management's will audio As Q&A to a be following a over Dror? available this the call to be

Dror Harats

you, and morning Lee good everyone. Thank

Amos productive and our it full-year novel to VBL is been lead program year for Chief XXXX. therapy with another important discuss our fourth will the results tumors. progress today's Officer our quarter and financial has pleased VB-XXX, say for quarter me on that solid milestones and developments, Financial continued who call for Ron, Joining I'm gene for achieved

a ongoing which currently to challenging platinum-resistant continue Phase where disease pivotal cancer, care enabling is has be with progress a if study ovarian Phase patients trial recurrent by the registration an We limited have placebo-controlled, of setting ovarian a OVAL successful OVAL had we ovarian in options. in cancer. X encouraged new standard cancer international To-date, potential positive reviews to X establish of in study. the our three double-blind

was XX conducted analysis, one interim we was an which when had first The evaluable patients.

of patients despite XXX the see enrolled with well information the we announced been high continue in had Enrollment the the first December, and population. study. the patient evaluable total over trial of to last CA-XXX As recent that forward VB-XXX the DSMC after in the issues. that the review, continuation the most DSMC European the we of set, planned, in at XXX at OVAL XXX reviewing light pandemic on in this after rate analysis third August the looking to safety during ongoing arm. green in we in COVID-XX response as again review looking the the February safety We the us arm XX% pleased recommended study in blinded a recently XXXX gave Data no Committee look quarter CA-XXX the a to March, in for that their say finding or proceed most XX% XXXX, reported progressed we of over of patient Later patients, the I'm had data or patients Monitoring higher DSMC, reported showed rate next data to year. a Safety response

Japan to to support our thrilled to for the approvals. authorities potential and population We’re be study Europe accelerate closer VB-XXX This the recruitment submission dialog to we soon expanding expansion regulatory patient diversify into regulatory further in base, is expected the as with and our of well. as study get

at to achieve this end effective early in enrollment therapy year expect other VB-XXX advanced. We of tumors with and XXXX. as demonstrating solid We continue the for OVAL safe patient or as to studies full a potential and hope

end, recurrent centers glioblastoma, recurrent recurrent Dana conducted or only. patient beyond neuro to several by in and the solid cancer, in tumors. And Phase after States. being VB-XXX will cell surgery neuro of GBM, been currently solid accordingly, Phase Phase United be the renal before announced is and collaboration have standard study that of a through VBL is X or that Cancer types. VB-XXX VB-XXX Institute are know, care of clinical to trials, arm scheduled for GBM. is you activity administrated surgery, for after medical several undergo and evaluating we Each leading with with other X Phase secondary As In sponsored treatment cancer. The patient has is VB-XXX and potential and patients the the X carcinoma, either compared be To enrolling drug endocrine ovarian study treatment Farber dosing potential trial century tumor control other and The who indications study a arm. between oncology will a X currently the in seen recently our tumor as has in we being studied VB-XXX initiated thyroid

sponsored by investigator the in is National cancer. being VB-XXX colorectal NCI conducted with metastatic Institute Cancer patient study or with Another

cold to in sharing the of the oral this X by control our the with treatment priming forward We randomized X investigational As expected to April more as we update prior this of The the patient We is from tumor. Virtual about data the R&D bring test addition followed study Day of OVAL of trial trial VB-XXX for on in severe are Phase we severe have X. mid-year. into indication, is study efficacy Tuesday, Phase safety look Preliminary and this to progressed. by proprietary don't nivolumab in any additional particular system whether upcoming this our data immune first VB-XXX purpose VB-XXX, details at with may the dosed study goal of investigate this VB-XXX molecule modulator the with to patients a providing is recently look in COVID-XX. COVID-XX and and immune trial forward

material, continue XXXX. advancing VB-XXX IND monoclonal is antibody we’re clean, submission We advance of far, also be which IND the very expected Thus half to GMP studies. that would our program preliminary first data in needed and enabling for of look toxicology our production grade through

I’d a year of to Financial XXXX progress that been like the hand I Chief for our has say call Before over to significant Amos VBL. Officer, Ron,

the We’re we with of the discuss again hand forward at who to look and all the I’ll off to sharing forward with our our will With you advancements Virtual encouraged by that, call R&D Day significant Tuesday, on financial speaking for April program the pipeline, please. through updates quarter ongoing XXXX. the Amos We on rest fourth to all results the and X. Amos, full-year. look

Amos Ron

Dror you, morning Thank good and everyone.

million capital million. As cash, deposits of had totaling December $XX.X $XX.X working deposits restricted XX bank XXXX, cash of and short-term we bank and equivalents,

the compared compared net period VB-XXX fund share and We sufficient $XX.X deposits XXXX. the or period share towards expect the operating was $XXX,XXX and the of into in Revenues call development fourth this equivalents the loss last the development million the be call. to year. in $X.X for the per $XX.X bank that, expenditure full-year I’ll of XXXX. quarter that to $X.X operator cash finally, requirements the year short-term year, $X.XX was the same back the $XX.X cash $XXX,XXX was question-and-answer compared expenses for expenses XXXX. of million IND. XXXX to in compared With XXXX. The fiscal due year, $X.XX for R&D morning’s to Research mainly million for $XX.X the period fiscal fiscal our was or in and expenses And and return in administrative the to capital million General and portion comprehensive million increase were for to per for million expense in to comparable as same will

Operator

at your a [Operator is we’ll Our question Swayampakula H.C. Ramakanth be Instructions] from question-and-answer conducting question. And from Dr. Wainwright. with proceed time, this session. first Please

Swayampakula Ramakanth

is you the questions. for couple Good ones. taking call of this quick Wainwright. from you, and H.C. A Amos, this Thank thank and afternoon, Dror RK

in quarter of trial, third in the you year. On this the interim next OVAL were the VB-XXX look talking about the

the So what And be data? are DSMB will the statistical the would also have on criteria any under the look into look the which of study plan or taking statistics the interim impact on this itself? a

Dror Harats

looking that? get data curve, the two at individually if Meier curve, They mean at Thank the DSMC they’re That's price this comparing resist statistical survival, a full a The They also safety registration rules don't the fashion for of but you, for the is CA-XXX. of they all including otherwise course between they’re again progression unblinded don't the same because the of every getting safe, the an plan see Kaplan that arms the the get to is any including the RK the at they as the patient big free is What trial. But routinely pay months. question. six drug safety, by response Kaplan trial. Meier to have in at this study we getting which are part unblinded every they looking end their looking data I do the have would and of just for and actually that. specific for we data survival

safety. of OS, combined the rate do the response the the So, they see basically, they whole a at resist, get The rate but for and full by quality both information company PFS, CA-XXX fashion. trial, of response also rate don't course point. and by full response the endpoints in data life the the see They questionnaires because don't blinded this each get of

VB-XXX not these because said is both all have we’re So response BLA no fever is on very roles. developed know be course, an trial there data we of Having a by we potentially a who get put rate careful. allowed by to trial. for who about resist, speak and did CA-XXX that specific also are understanding to not but this This to both that, we registration the

has in good treatment there course, that of prolong other trial, when is obligations, some usually DSMC Of no which especially this clinical are life. can type

test, early. then decision they major in flag and is agency raise the life if trial if they for improvement to to can should with a a or no do specific a rule stop and meeting So a you that. there always make a when see But request in significant response expectancy, specific

Swayampakula Ramakanth

and on and trial, something I'm previous the just you And Phase have contrast, GBM surgery, recurrent the thank I straight can had have talking you’re that in that. make design Phase trial, head. design then to X my versus current studies, X it before the sure trying you for the you the Okay, compare and during about after because

Dror Harats

more Okay, you in this, together can kept so and the papers Phase debulking. and one or patients even the that and sometime Avastin this with that about because and one wanted surgery, them other was we if the coming in but disease of priming VB-XXX took Phase the radiotherapy had neuro-oncology, published day the X first have that trial it's chemotherapy, the Avastin the as and way also to they’re know similar one, the in of is VB-XXX. surgery, Again, Avastin failed same times already because or surgery or anyway, got a radiation, tissue through second we we primed, surgery, and actually doing than creating go failed was then a VB-XXX And it wanted so three out cells molecular GBM, expression immune the VB-XXX trial in saying recurrent actually see alone other recurrent of get blocked But when times actually actually all they we Avastin couple if cancer into because sometimes And change tumor, important second a get was I patient course, patients debulking of population, same patients unfortunate the with tissue we anyway, for in would to in immune GBM, control, running, and going driven when edema back, and goes the to of many one of test sort actually indeed give if and failed progressed, In we’re go chemotherapy, which group because basically the now the as because third a GBM, you is a we steroid. now who Phase surgery, are to and can tumor. from now to because coming randomized into three, the we was is biology of of chemotherapy, they there that surgery drug brain trial But progressed, had in that drug, then an drug, surgery, could that play get come therapies. they oncology second radiation. a a use population as to many Avastin actually lot the we on is we’re of information which failed know, it we when they're failed before it's they a group with that that in them them super progression, was going got that find a of this X on allow the they failed into they’re that's failed recurrent groups. X sort ovarian lesions we divided immune there getting for when

Before Group to get to going with getting care. tumor the see A we’re on got blinded placebo. can get if Group standard course, surgery, And now before on that it's surgery, neoadjuvant is C that Group going Group VB-XXX, is and VB-XXX keeping anymore. adjuvant therapy biology. C on look is randomized Group After A VB-XXX, has go got any and A not everything the and of to placebo B the effect drug are blindly the will any and of blinded

there. start So the what an therapy important when this? of we to any right because gaining therapy oncology, therapy neoadjuvant are be therapy that that We’re VB-XXX know to is But we recurrent in care a from actually like compare study tumor it comparing might the adjuvant in standard to we is now GBM. immune the also

Swayampakula Ramakanth

of Perfect, is this? study a how large

Dror Harats

not So a big It's trial. it's actually a very trial. small a

in patients XX a group. have We

indication, but patients, So controlled all and to trial this XX it's together you show compare we can months sometimes when and survival. patients blinded, XX that know it's six PFS in randomized, you even overall XX

endpoint, PFS, whole actually as secondary we is and positive show in for early And have as secondary for the the primary the primary a surrogate idea we’re actually endpoint if months, a OS. a will to the marker and indeed having So six in years. is strong endpoint, there drug a is GBM and extremely There trend new this even the last a drug in no registration chance XX this needed field. in endpoint

Swayampakula Ramakanth

of that. trial, get out last I queue, one I of COVID-XX in absolutely. Then you're Absolutely, question and before into Japan understand Europe. the step outside Israel I on the moving

so looked the being So, at patients. bigger other these also there for therapies many that what for are and which are strategy COVID-XX is

study are your So guys how what differentiate other do you doing? versus

Dror Harats

monocytes COVID-XX, RK, indeed migration. migration, early it's effect Israel X XXX while only an see What's being we on the right extending our to market. the unique that's trial maybe earlier even in Europe tissues we’re directly is and understand driven injury having now. human VB-XXX one on actually to running we’re OVAL monocyte like can to in put block stuff working that about the I like was the the And And pneumonia, showed actually that past and can to misunderstood, know of you trial just disease we Japan. VB-XXX a is the doing myocarditis if already the is the trials. Phase that drug international on its in monocytes trial that COVID-XX. And it, drug and in

are we it. why that's testing So

very right the Now in is good. Israel now condition

proportion You that immunized. big population were of the know

our to Right or trial we Israel now we have not. the we patients if thinking, extend beyond to want many actually new have Israel. now, don't with So in to COVID-XX

Swayampakula Ramakanth

Thank you. all taking questions. you for my Thank

Dror Harats

Thank you.

Operator

with DeGeeter your Our next question question. proceed is Kevin with Please from Oppenheimer.

Unidentified Analyst

this Kevin you Hi, taking Thank in calling morning. is this DeGeeter. for Susan questions for my

Japan? guys sites. VB-XXX a sites the open? study update in And then Can of follow-up, timeline So OVAL currently first I on it follow-up sites Europe first to initiating just enrollment August. provide and an your what's You you actually in number mentioned for wanted as on

So it's quite months. a been few

Dror Harats

you, thank so Okay, Susan.

we first COVID-XX changing four XX three it's to now recruiting not only question, believe open are the think or more I right actually now. every that have the than that centers day. But For And due centers I internationally.

So Actually, the in Poland, that centers we it's And actually And soon. right in very we centers now. it's have almost open. all them Poland. U.S., open now intend are the Europe, and in we Israel, opened in to in have Spain open Spain, right in centers U.K. in and in Europe, it’s XX it's

terms patient there going soon. very In of well. It's very well announce as first we’ll Japan, dosing

Unidentified Analyst

And programs. question program Can and be? you this the when of color questions a I studies the enrollment or MOSPDX what the study. want provide venue on second just on And appropriate, the is see to what couple colorectal then tox metastatic the for appropriate cancer might more my status then some was. know on other to data

last I to what should sort think we see? said of patients three data you preliminary time and expect the there's

Dror Harats

MOSPDX for rodents toxicology ranging monkeys, So, in toxicology clear. each the dose came and to both we study formal did in and completely study,

we the and quite costly. far. so you there batch, the detect can after that was to no that the in this. been imagine high reassured as trial the weeks so results we if on know, well. toxicology make ended go we’re And can and But that GMP So very waiting for would can we've basically, for is It we pull for the and already you say before as report, histology the trigger we dose all gross looks far decided this the pathology. study, clean, studies four we is including anything I in final But which could the report

all And tumor immune prevalent enjoying it solid you just market, I it's oncology is I'm calls clarify mainly to public. no system and what patient real the a it of XX% not to trial, they’re that glad call the major checkpoint therefore, which that's not the is checkpoint audience so tract both cold response and Colorectal female. we And male whole there the the GI problem from there. the colorectal, disease. And a high tumor, a this Regarding question which asked a biggest It's don't want for CRC new inhibitors. basically oncology, cancer to means because the to have there tumor that it's inhibitors.

Now, in we don't preliminary results have field. this

lesion. can one did trial results you a here the like with thyroid is is didn't major that that. us we the a can why So ask there to cancer that forward do trial, start stuff renal into NCI with us bring go and we and such and immune this good need cancer, and ovarian had this reason very But came metastatic to especially after the you tumor so or people offered that here preliminary the system

relatively So or I on a National trial the see would Cancer say we’re have what we small than funded knowledge or And no chance. call doctors But on this mainly that anybody is this to actually going else. anybody the trial. by it else early I is more Institute. actually a is this gave

see clinical do recruited we taking results turn see meaningful already And colorectal was stage a there XX cancer to a small this indeed, So and tumor. we a trial, a tumor patients because I very late point we’re it expect to to the wouldn't patient. can cold trial. from to it's if

cancer, is But the the the know can organs. the immune we other system different know imagine in bringing we’re progressing in that GI indeed biology than you completely don't it's well. if the colon system So immune into for that I

So to it be remains seen.

Unidentified Analyst

all for That's I you my had. thank Great, question. answering

Operator

Please with [Operator with Jonathan Partners. your Instructions] question proceed Our from is ROTH Aschoff question. next Capital

Jonathan Aschoff

Thank recent in you. does alter your about Phase the Rucaparib way treatment? Chemo plus thinking ovarian results Dror, cancer X any refractory

Dror Harats

repeat referring you Can trial that you're on to? the

Jonathan Aschoff

about Does altering plus X, in space Rucaparib your thinking that minus? it's the recent The Phase Rucaparib any or way?

Dror Harats

in quite important stage. in that really. is patients, tell positive, the world, and they inhibitors BRCA XX%. the in early a work Israel you it's prevalent because gene work prevalent inhibitors it’s the ovarian they especially Not Ashkenazi Jews, in about and BRCA are cancer, it's PARP I'll work which And but later in in why. know we positive PARP

patients you it's I'm inhibitors. ask think lot have the the yourself even cannot surprised So because inhibitors when when taking you with they at continue effects about why positive, lot all. of BRCA PARP PARP PARP and not But side inhibitors of a a the of

Phase So happy landscape really to will but Avastin not XX% is of recruit we now think I just in I'm the indication. what always on you be are look for and at such have because changed that we results, in the don't are the it's trial. drug final failure one patient know, OVAL we so And there you and patients XX% see But what X not solve this believed difficult far that's it's very failed the of if inhibitors. for going actually that our problem that I trial, the failure, PARP that already

generally this some So in almost taking survival, failed fine. survival, bit the them worse. they And of that that for patients expect PARP any therapies, of when show at me in would this sometimes VBL chemotherapy, not with disappoint the very sick at evidence just on And you better when don't even ovarian bit a some do field is you that was a for already that's indication. a will with but trial not efficacy we're inhibitor What little they I everything. combine population look when do

do will So tell case I opposite. see want the survival. agency now your that any that in VB-XXX approval, before drug not believe is I And the actually will that you hurting can to

Jonathan Aschoff

is you which the were said say patients what that. wondering, rate you in the anything Thank interim about fever? you believe with first and can fever I response I XX at CA-XXX was there for beyond

Dror Harats

for tell at very they is agency be They this issue fever and patients so because everything, it all XXX interaction know because terms, some everybody will you Yes, and fever. in we careful. as to a on the of was on way, a are is of response the XX% CMC then that they’re in it then serious develop trial. with then, how look the XX% the a in And since ready drug. have can the registration that the and I and BLA because trials unblind we And very patients doctors actually rate

So about emphasize we have too with asked not why much the And we’re anything. been not what that's happened to saying fever.

can it a As we PFS because do we to a see say data. response always, you resist population do the word data. and the And we see total imagine, asked about we've because do And it. see But in we see everything. the do do we not been the see

Jonathan Aschoff

think for how Amos of we that the saw SG&A over quarter-over-quarter Okay, that the finally, fourth should year this given line we doubling quarter about ‘XX?

Amos Ron

we Please the in the question don't the because doubling SG&A quarter. see of repeat

Jonathan Aschoff

To for last get $X a million in like to million your annual quarter quarters? roughly numbers, the the versus the three quarter SG&A $X.X was fourth

Amos Ron

for this So very the in expenses between just are XXXX. expenses year timesheets similar were is the all-in-all in G&A that those to

Jonathan Aschoff

thank guys. you Okay,

Dror Harats

Thank you.

Operator

Research. Our is Kreizman next Please question. proceed Valore your from question with with Jonathan

Jonathan Kreizman

Amos. Thanks Hi, Dror, question. taking for the

you VBL-XXX Dror that earlier be modalities. So, in additional could studied mentioned

scientific VBL-XXX approach you will first were additional be an what initiate trial would gathered ones indication the besides considering if running, you the to-date? that already to So, for know data you the

Dror Harats

preliminary And lead we think for to is there ovarian, indication I the and and on VB-XXX so first ovarian. ovarian have indication that think very ovarian, good be one is indication focused I the the Okay, data. has which lead

has that's the patient Phase biopsies. convince of the we thing I making you States. We is we’re centers and that United patient. view cancer, where GBM, the I it run doing had are, we and it, and patient which there where happened a the The the would to and the the even trial. in do by treat Colon for told and work in then But major we tract it's actually anything more interim reason that have We sense it and in do new way trying agreed the in not are to the of why two trial, will. actually actually was us is community the believe approaching a preliminary the concentrated in doing to results a And actually lot major we need gut, do because doctors say in we because the lot that's what if us also X again, right In way have doing the that we can biologic we’re oncology. Phase trials data know I way in VB-XXX more trial I'm to open But questions immune just if knew sure we GI the it system why data does, X. and to

important insert, we lung, The lung, other the in definitely actually that working for indications that the lung. had is should very we it's in go the we know immune is oncology

drug especially liver go actually know adenovector in to that it working Phase be good we is in is crowded. liver brain a also metastasis, very we working metastases, will in we that the it's the reason that that and quantities that is know liver, in one believe work clear in So know metastases. there deliver, we thing, to renal, quite renal that's the should X in saw quite brain And it a good and

can list because So I big the find show strategic where initiated then work I are will immune tumor in you actually a system on tumor only investigator into And saying difference like saw say solid as can VB-XXX don't having you of partner most immune cold on change tumor, actually it especially VB-XXX system. will heard the actually that in that that trial, go type different tumors think oncology, be make GI right parallel are some other There a that believe either way market. turn small modalities. and forward an that tumors where is from tract hot is we of about is we’ll the Checkpoint the organs, I solid for already or do indications like in with is to you patients, a these that will a know, after can trials know we big immune a a that we me saying some be there. oncology because a And trials, a what between inhibitors of different XX% positive there, in I completely it is because But it already with would alone immune we tumor. different indications working should drug also that the is believe there combine I'm I there. drug fame thyroid, when of step indications different think

different. it's So

Jonathan Kreizman

Great. you effectiveness made potential some colorectal following-up on And cancer. today then on on comments

So of drug action to the would work mechanism be you threshold of in immune column would in the and this the mentioned result able a turn happy be realistically the system actually like about that, to the it's to what be or one? particular biology matter you the of the

Dror Harats

we major So the bring tumor recognize the anything show would tumor that be that that immune can a the will system achievement. to and

tolerance from we in these all You new food. GI, coming have a the because having we’re know big that antigens

bring if of the it's that the this tumors. surprising not coldest is immune So mechanism, there. question is of by the And system we indeed can type the one

want ovarian for PFS looking what looks, other invest more with actually in not just is or really treat trials not seeing we will that to actually the to if how very is to this to OS organ we’re sick small, in need much that in the or similar right not? patients, in VB-XXX. see I'm the So it the us we And GI this or tell Tract biopsies actually

Jonathan Kreizman

in VB-XXX COVID-XX. Okay, then on

to there more been clinical I So, has the XX noticed guess pandemic decided molecule months ago. whereas initiate And the a time. just basically has trial you for than pretty recently I long the struck

to was particular the I this your hear behind of the curious initiating So trial thoughts timing in period?

Dror Harats

we Well, to into develop trial the for it's block history, could we can this Phase show But why And a data, atherosclerosis. at type enough big getting compete it's a primary need keep that tried point. the a very in will trial. biologics. developed going of on trial, that it saw atherosclerosis, And drug a lesion, an developing T-cell the it more of for about we some be other in with was endpoint drug strong was that's practical not we And inflammation. being, that will not to you in atherosclerotic decided anti-inflammatory monocytes indeed, we human wasn't but indication really to actually in it's X which actually beginning positive to from where

capsules that two when is monocytes we after can clear disease. this the acute it months, three will we or do show that, and quite patients we trial. the that needed the go an in and moment a for So try had that invested this. decision And Israel, make COVID-XX trial. doing we to to reeving started actually and make But and enough we And again it another start, the back the the we have we everything and disease relatively in API was early, here and was

assure the or actually can viral monocytes that diseases just think driven indication. in not And chronic viral right I drug virus, in that the story, is mechanism I It's of COVID-XX. can even Now, solving because viral with infection, the it clear unique action, work quite COVID-XX and we’ll is an this injury to you because now that infection the in of it's find in tissues. target

Jonathan Kreizman

Go ahead.

Dror Harats

are the vascular in now in shorter in itself, story. but And inflammation expectancy the be and in organs. general, the arteries, they a again HIV of not chronic heart happened life to from have other monocyte it the much Patients dying because

Jonathan Kreizman

position. And cash thanks. on Okay, the then lastly

a gives cash company the position ‘XX. into the mentioned runway you So now QX

If can some maybe more bit this share guidance. into you detail

one, prior ‘XX the the has been that company the injected in was I So cash third the out just the trying range quarter last to for quarter? basically, to and figure of if recall

Amos Ron

Sure.

of during Capital we quarter first $XX.X LLC. from of warrants had of the million sales injection APM So ‘XX, by Aspire exercise and purchases from from the

So this have enough the balance. question? fourth take quarter we now ‘XX. address into cash Therefore, of to that cash increased our us your Does

Jonathan Kreizman

issued just May they how, back outstanding still Yes, on XXXX are and then in the have if warrants exhausted? you touch of been what already or if could maybe percentage

Amos Ron

the than $X have warrant yet was So less in million. and And little January of about February. outstanding, half exercised we about

Jonathan Kreizman

for Okay, great. Thanks detail. the

Operator

over now the the have VBL session. the the of question-and-answer for remarks. closing reached we turn end to And team I'll call

Dror Harats

for on So us joining a day. thank you our call wonderful have today. all And

Operator

and at your you conference Thank lines you today’s participation. concludes this may And your you. Thank for disconnect this time.

Notable Labs (NTBLQ) 25 Mar 212020 Q4 Earnings call transcript